Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Takeover Mania is Coming!!! -- Ignore unavailable to you. Want to Upgrade?

To: gfp927z who wrote (1)	7/17/2005 1:40:58 PM
From: Arthur Radley	Read Replies (1) \| Respond to of 49

gfp, Excellent selections! Especially IMO is CBST. The PFE/MICU deal points out the need in this area. Our current antibiotic medicines are quickly losing their ability to fight infections(we as a population vastly overuse our current antibiotics not fully realizing that one day we will really will need them)and when you add the inherent problems of developing newer ones because of the immune system issue one can understand why PFE was so willing to pay that 70%+ premium. I thought at the time why PFE didn't go for CBST instead of MICU since CBST had already received FDA approval and MICU had encountered some difficulty. But then I had a few MICU shares and didn't own any CBST...so wasn't that upset. Your Vertex is also a good selection.